Prevision Policy Clips | Trump Praises MAHA Commission, Announces “Reciprocal Tariffs” On April 2

Prevision Policy Clips | Drug Prices, Pharma Tariffs And Medicaid Cuts Are Topics To Watch For During President Trump's Address

Prevision Policy Clips | FDA Return To Office Procedures Are Underway; Initial Process Is Relatively Smooth

Controlled Correspondence: FDA Encourages Generic Sponsors To Ask Better Questions; SBIA Event Includes Plea For Industry To Affirm Value Of FDA Public Meetings

FDA Deadline Tracker: No Sign Of Slippage On Drug Reviews In First Month Under Trump

Prevision Policy Clips | FDA Commissioner Nominee Makary Set For March 6 Confirmation Hearing

Advisory Committee Tracker: FDA Resumes Public Speaking Engagements – But Advisory Committees Still MIA

PRV Renewal, PBM Reform Are Bipartisan Issues At House Health Subcommittee Hearing But Pathway Is “Uncertain”

FDA’s Next DOGE Test: How Will “Maximum” Cuts Be Defined For Agency Under OMB Memo Implementing Trump Executive Order

Prevision Policy Clips | DOGE Phase 2: OMB Guidance Calls For Agency RIF And Reorganization Plans (ARRP) By March 13

Cell Therapy Regulatory Revamp Could Mirror Device Regulations: A Risk-Based System Would Encourage Development And Discourage “Bad Actors,” CBER Says

Prevision Policy Clips | FDA Shutters Clozapine REMS

FDA Drug/Biologic Review Largely Insulated From DOGE RIFs So Far; Communications Freeze (Sort Of) Lifted

GLP-1 Pushback? HHS Inspector General Flags Surging Use Of Anti-Diabetics, Suggests Scripts May Be Outside “Medically Accepted Indications”

Prevision Policy Clips | CBER’s Marks And Verdun Deliver Opening Remarks At HCT/P Workshop

House Energy & Commerce Committee Plans To Highlight Downsides Of Price Negotiation In 119th Congress; Domestic Manufacturing, Chronic Diseases Among Other Topics On Oversight Agenda

Prevision Policy Clips | Medicare Price Negotiation: CMS Sets Dates For Roundtable, Town Hall Events

FDA Retirements And Departures: CDER Changes Include Departures Of Pain Medicine, Non-Malignant Hematology Division Leaders; CBER Deputy Witten Has Retired

Prevision Policy Clips | Vaccine Disruption Begins: ACIP Meeting Postponed

Medicare Adds Former Trump I Official Aramanda As Principal Deputy Director; Former OMBer Albanese Is Policy Advisor

Prevision Policy Clips | CBER Gene/Cell Therapy Leadership Team Appears Set For First Public Presentations Of Trump Era

Make HHS Anti-Industry Again? Kennedy Blames “System, Not The People,” For “Inefficient, Dysfunctional Or Corrupt” Agencies In First Address To Staff

Prevision Policy Clips | Disrupting FDA: Agency Managers Unsure Of Who Is Laid Off Until Notified By Affected Staff

Prevision Policy Clips | FDA Layoffs Begin: Device Center Appears More Affected In Round One

The Kennedy HHS Era Begins With FDA Staff On Edge: “MAHA” Commission Launches With Anti-Industry Themes – But Better Than Some Alternatives